Lumida
/LRMR
⌘K
Larimar Therapeutics Inc

Larimar Therapeutics Inc

LRMR
$3.70USD+0.82%+0.03 today

MARKET CAP

384.4M

P/E (TTM)

FWD P/E

DAY RANGE

$4 – $4

52W RANGE

$3
$6

AI Summary

Stalk
Sell NowMedium

LRMR is in a Stage 4 decline with price making lower highs and lower lows beneath declining EMAs. The medium-term bias is bearish, and short-term behavior shows rejection at the 9/21 EMA zone, presenting an immediate sell opportunity. Support remains absent until price can reclaim intermediate moving averages, so selling into the current bounce is warranted.

  • Cash reserves of ~$178M with minimal debt secure runway into 2027.
  • First BLA module submitted for nomlabofusp; sustained frataxin levels noted.
  • Anaphylaxis in 10/41 patients raises regulatory approval risk.
Full analysis →
Insider Trades1 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Dec 7, 2023BuyLRMRGopi ShankarChief Development Officer5,000$3.73$384.4M-42.37%+36.28%$18.7KSell Now